肝癌微创治疗对机体T淋巴细胞亚群影响的研究现状

Research status of the impact analysis of organism T-lymphocyte subsets with liver cancer Interventional postoperation

目的:总结肝癌微创治疗前后(化疗栓塞术、氩氦冷冻、射频消融等)机体T淋巴细胞亚群变化特点,探讨其对机体免疫功能的影响。方法:应用PubMed和万方等数据检索系统,以"微创治疗、T淋巴细胞亚群"等为关键词,检索2005-01-2011-12的相关文献,纳入标准:1)微创治疗肝癌;2)T淋巴细胞亚群发生免疫功能变化的研究。纳入符合标准的13篇相关文献分析。结果:微创治疗肝癌临床上与手术切除不同之处在于治疗后肿瘤是在体内被灭活,体内坏死的肿瘤组织诱导机体自身抗肿瘤免疫产生,大量研究证实术后CD3+、CD4+、CD4+/CD8+均升高,而CD8+降低,活化T细胞亚群增多,机体免疫功能增强,预后明显得到改善。结论:有效评估微创治疗后肝癌患者的细胞免疫功能水平,为联合免疫治疗在内以介入微创治疗为主的肝癌综合治疗提供理论依据。

OBJECTIVE： To summarize the changes in the T-lymphocyte subsets characteristics of hepatocellular carcinoma after the minimally interventional treatment （chemoembolization, cryoablation, radiofrequency ablation etc. ）, and explore influence on immune function. METHODS： The PubMed and Wanfang Data were searched using the key words ＂minimally interventional, T-lymphocyte subsets etc. ＂, from 2005-01 to 2011-12. The inclusion criteria： 1） the mini- mally interventional treatment of hepatocellular carcinoma; 2）the change of T-lymphocyte subsets immune function. Ac- cording to the above criteria, 13 papers were finally analyzed. RESULTS： The minimally interventional treatment of hepa- tocellular carcinoma different from the surgical resection or liver transplantation is that the tumor is inactivated in vivo and the tumor necrosis may induce or activate the body＇s own anti-tumor immunity. Many studies confirmed that CD3＋ , CD4＋ ,CD4＋/CD8＋ were higher and CD8＋ was lower after treatment,activated T-lymphocyte subsets increased and im- mune function improved obviously and prognosis of patients improved. CONCLUSION： Effectively assess cellular immune function in patients with HCC postoperation can lay the groundwork and provide a clear theoretical basis for interventional comprehensive treatment,joining with immune therapy.